Intragenic integration in DLC1 sustains factor VIII expression in primary human cells without insertional oncogenicity
Authors:
Open Access
- 20 February 2014
- journal article
- Published by Springer Nature in Gene Therapy
- Vol. 21 (4) , 402-412
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- Precision genome engineering with programmable DNA-nicking enzymesGenome Research, 2012
- Long-Term Expression of Human Coagulation Factor VIII in a Tolerant Mouse Model Using the φC31 Integrase SystemHuman Gene Therapy, 2012
- A novel isoform of the 8p22 tumor suppressor gene DLC1 suppresses tumor growth and is frequently silenced in multiple common tumorsOncogene, 2011
- Stem-Cell Gene Therapy for the Wiskott–Aldrich SyndromeNew England Journal of Medicine, 2010
- Biosafety Assessment of Site-directed Transgene Integration in Human Umbilical Cord–lining CellsMolecular Therapy, 2010
- Directed Engineering of a High-expression Chimeric Transgene as a Strategy for Gene Therapy of Hemophilia AMolecular Therapy, 2009
- DNA bar coding and pyrosequencing to analyze adverse events in therapeutic gene transferNucleic Acids Research, 2008
- Deleted in liver cancer-1 (DLC-1): A tumor suppressor not just for liverThe International Journal of Biochemistry & Cell Biology, 2008
- Prospective identification of tumorigenic breast cancer cellsProceedings of the National Academy of Sciences, 2003
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001